<?xml version="1.0" encoding="utf-8"?><feed xmlns="http://www.w3.org/2005/Atom" ><generator uri="https://jekyllrb.com/" version="4.3.2">Jekyll</generator><link href="https://marchionnilab.org/feed.xml" rel="self" type="application/atom+xml" /><link href="https://marchionnilab.org/" rel="alternate" type="text/html" /><updated>2025-02-24T20:11:45+00:00</updated><id>https://marchionnilab.org/feed.xml</id><title type="html">Marchionni Lab</title><subtitle>A short overview of our research and projects</subtitle><entry><title type="html">Notch gene signature for neoadjuvant chemotherapy response in triple-negative breast cancer</title><link href="https://marchionnilab.org/2024/11/15/post-1.html" rel="alternate" type="text/html" title="Notch gene signature for neoadjuvant chemotherapy response in triple-negative breast cancer" /><published>2024-11-15T00:00:00+00:00</published><updated>2025-02-24T20:09:32+00:00</updated><id>https://marchionnilab.org/2024/11/15/post-1</id><content type="html" xml:base="https://marchionnilab.org/2024/11/15/post-1.html"><![CDATA[<h1 id="notch-based-gene-signature-for-predicting-the-response-to-neoadjuvant-chemotherapy-in-triple-negative-breast-cancer"><em>Notch-based gene signature for predicting the response to neoadjuvant chemotherapy in triple-negative breast cancer</em></h1>

<div class="search-info"></div>

<p>Background: Neoadjuvant chemotherapy (NACT) is widely accepted as a treatment for triple-negative breast cancer (TNBC), but not all patients benefit from it. There are currently no validated biomarkers to predict the response to NACT, and previous attempts to create predictive classifiers using gene expression data have lacked clinical relevance. However, models that integrate biological constraints have shown improved robustness and performance compared to agnostic classifiers.</p>

<p>Methods: We utilized preoperative transcriptomic profiles from 298 TNBC patients to train and evaluate a rank-based classifier, k-top scoring pairs, designed to predict whether a patient will achieve pathological complete response (pCR) or have residual disease (RD) after NACT. To minimize overfitting and enhance the signature’s interpretability, we focused on genes involved in the Notch signaling pathway during the training process. The model was then tested on two independent patient cohorts, comprising 75 and 71 patients, respectively. Additionally, we examined the signature’s prognostic value by investigating its correlation with relapse-free survival (RFS) through Kaplan‒Meier (KM) survival estimates and a multivariate Cox proportional hazards model.</p>

<p>Results: The final signature, consisting of five gene pairs, can predict NACT response based on their relative ordering. The model demonstrated robust performance in predicting pCR in TNBC patients, with an area under the ROC curve (AUC) of 0.76 and 0.85 in the first and second test cohorts, respectively. It outperformed other gene signatures developed for similar purposes. Furthermore, the signature was significantly associated with RFS in an independent TNBC cohort, even after adjusting for factors such as T stage, patient age at diagnosis, type of surgery, and menopausal status.</p>

<p>Conclusion: We present a robust gene signature that predicts pathological complete response (pCR) in TNBC patients. This signature uses easily interpretable, rank-based decision rules focused on genes regulated by the Notch signaling pathway, which plays a key role in breast cancer chemoresistance. The signature’s strong predictive and prognostic capabilities make it a promising tool for clinical use, assisting in the stratification of TNBC patients undergoing NACT.</p>

<div class="citation-container">
  <div class="citation">
    
      <a href="https://www.ncbi.nlm.nih.gov/pubmed/37964363" class="citation-image" aria-label="Notch-based gene signature for predicting the response to neoadjuvant chemotherapy in triple-negative breast cancer.">
        <img src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0342/10647131/e40db7c7b497/12967_2023_4713_Fig1_HTML.jpg" alt="Notch-based gene signature for predicting the response to neoadjuvant chemotherapy in triple-negative breast cancer." loading="lazy" onerror="this.src = '/images/fallback.svg'; this.onerror = null;" />
      </a>
    

    <div class="citation-text">
      
      

      <a href="https://www.ncbi.nlm.nih.gov/pubmed/37964363" class="citation-title">
        Notch-based gene signature for predicting the response to neoadjuvant chemotherapy in triple-negative breast cancer.
      </a>

      <div class="citation-authors" tabindex="0">
        Mohamed Omar, Pier Vitale Nuzzo, Francesco Ravera, Sara Bleve, Giuseppe Nicolò Fanelli, Claudio Zanettini, Itzel Valencia, Luigi Marchionni

      </div>

      <div class="citation-details">
        <span class="citation-publisher">Journal of translational medicine</span>
        &nbsp;·&nbsp;
        <span class="citation-date">15 Nov 2023</span>
        &nbsp;·&nbsp;
        <span class="citation-id">pubmed:37964363</span>
      </div>

      
        

        

        
          


  <div class="tags">
    
      <a href="?search=&quot;tag: method&quot;" class="tag" data-tooltip="Show items with the tag &quot;method&quot;">
        method
      </a>
    
      <a href="?search=&quot;tag: structural-variants&quot;" class="tag" data-tooltip="Show items with the tag &quot;structural-variants&quot;">
        structural-variants
      </a>
    
  </div>


        
      
    </div>
  </div>
</div>]]></content><author><name>luigi-marchionni</name></author><category term="gene signature" /><category term="cancer" /><category term="class prediction" /><category term="Notch signaling" /><category term="triple negative breast cancer" /><category term="neoadjuvant chemotherapy" /><summary type="html"><![CDATA[Notch-based gene signature for predicting the response to neoadjuvant chemotherapy in triple-negative breast cancer]]></summary><media:thumbnail xmlns:media="http://search.yahoo.com/mrss/" url="https://marchionnilab.org/images/science/Notch.png" /><media:content medium="image" url="https://marchionnilab.org/images/science/Notch.png" xmlns:media="http://search.yahoo.com/mrss/" /></entry><entry><title type="html">Meteorin-like protein in cancer immune evasion</title><link href="https://marchionnilab.org/2024/07/06/post-1.html" rel="alternate" type="text/html" title="Meteorin-like protein in cancer immune evasion" /><published>2024-07-06T00:00:00+00:00</published><updated>2025-02-24T20:09:32+00:00</updated><id>https://marchionnilab.org/2024/07/06/post-1</id><content type="html" xml:base="https://marchionnilab.org/2024/07/06/post-1.html"><![CDATA[<h1 id="the-cytokine-meteorin-like-inhibits-anti-tumor-cd8">The cytokine Meteorin-like inhibits anti-tumor CD8</h1>

<div class="search-info"></div>

<p>Tumor-infiltrating lymphocyte (TIL) hypofunction plays a key role in the progression of advanced cancers and is a common target for immunotherapy. Emerging evidence suggests that metabolic deficiencies contribute to T cell dysfunction during tonic stimulation, but the signals triggering metabolic reprogramming in this context are still poorly understood. In this study, we identified Meteorin-like (METRNL), a metabolically active cytokine secreted by immune cells within the tumor microenvironment (TME), as a factor causing bioenergetic failure in CD8+ T cells. METRNL was released by CD8+ T cells after repeated stimulation and acted through both autocrine and paracrine signaling mechanisms. We found that METRNL enhanced E2F-peroxisome proliferator-activated receptor delta (PPARδ) activity, leading to mitochondrial depolarization and reduced oxidative phosphorylation. This triggered a compensatory shift in bioenergetics towards glycolysis. Deleting or downregulating Metrnl improved the metabolic health of CD8+ T cells and boosted tumor control in several tumor models, suggesting that targeting the METRNL-E2F-PPARδ pathway may be a promising strategy to enhance the bioenergetic fitness of CD8+ TILs.</p>

<div class="citation-container">
  <div class="citation">
    
      <a href="https://www.ncbi.nlm.nih.gov/pubmed/39111315" class="citation-image" aria-label="The cytokine Meteorin-like inhibits anti-tumor CD8">
        <img src="https://ars.els-cdn.com/content/image/1-s2.0-S1074761324003522-fx1.jpg" alt="The cytokine Meteorin-like inhibits anti-tumor CD8" loading="lazy" onerror="this.src = '/images/fallback.svg'; this.onerror = null;" />
      </a>
    

    <div class="citation-text">
      
      

      <a href="https://www.ncbi.nlm.nih.gov/pubmed/39111315" class="citation-title">
        The cytokine Meteorin-like inhibits anti-tumor CD8
      </a>

      <div class="citation-authors" data-tooltip="Christopher M Jackson, Ayush Pant, Wikum Dinalankara, John Choi, Aanchal Jain, Ryan Nitta, Eli Yazigi, Laura Saleh, Liang Zhao, Thomas R Nirschl, Christina M Kochel, Brandon Hwa-Lin Bergsneider, Denis Routkevitch, Kisha Patel, Kwang Bog Cho, Stephany Tzeng, Sarah Y Neshat, Young-Hoon Kim, Barbara J Smith, Maria Cecilia Ramello, Elena Sotillo, Xinnan Wang, Jordan J Green, Chetan Bettegowda, Gordon Li, Henry Brem, Crystal L Mackall, Drew M Pardoll, Charles G Drake, Luigi Marchionni, Michael Lim" tabindex="0">
        Christopher M Jackson, Ayush Pant, Wikum Dinalankara, John Choi, Aanchal Jain, …, Crystal L Mackall, Drew M Pardoll, Charles G Drake, Luigi Marchionni, Michael Lim

      </div>

      <div class="citation-details">
        <span class="citation-publisher">Immunity</span>
        &nbsp;·&nbsp;
        <span class="citation-date">06 Aug 2024</span>
        &nbsp;·&nbsp;
        <span class="citation-id">pubmed:39111315</span>
      </div>

      
        

        

        
          


  <div class="tags">
    
      <a href="?search=&quot;tag: genomics&quot;" class="tag" data-tooltip="Show items with the tag &quot;genomics&quot;">
        genomics
      </a>
    
      <a href="?search=&quot;tag: transcriptomics&quot;" class="tag" data-tooltip="Show items with the tag &quot;transcriptomics&quot;">
        transcriptomics
      </a>
    
      <a href="?search=&quot;tag: cancer&quot;" class="tag" data-tooltip="Show items with the tag &quot;cancer&quot;">
        cancer
      </a>
    
      <a href="?search=&quot;tag: immunity&quot;" class="tag" data-tooltip="Show items with the tag &quot;immunity&quot;">
        immunity
      </a>
    
      <a href="?search=&quot;tag: tme&quot;" class="tag" data-tooltip="Show items with the tag &quot;tme&quot;">
        tme
      </a>
    
  </div>


        
      
    </div>
  </div>
</div>]]></content><author><name>luigi-marchionni</name></author><category term="medicine" /><category term="cancer" /><category term="class prediction" /><category term="metabolism" /><category term="immunotherapy" /><summary type="html"><![CDATA[The cytokine Meteorin-like inhibits anti-tumor CD8]]></summary><media:thumbnail xmlns:media="http://search.yahoo.com/mrss/" url="https://marchionnilab.org/images/science/METRNL.jpg" /><media:content medium="image" url="https://marchionnilab.org/images/science/METRNL.jpg" xmlns:media="http://search.yahoo.com/mrss/" /></entry><entry><title type="html">Interpretable phenotype-aware models</title><link href="https://marchionnilab.org/2023/11/28/post-1.html" rel="alternate" type="text/html" title="Interpretable phenotype-aware models" /><published>2023-11-28T00:00:00+00:00</published><updated>2025-02-24T20:09:32+00:00</updated><id>https://marchionnilab.org/2023/11/28/post-1</id><content type="html" xml:base="https://marchionnilab.org/2023/11/28/post-1.html"><![CDATA[<h1 id="phenosv-interpretable-phenotype-aware-model-for-the-prioritization-of-genes-affected-by-structural-variants">PhenoSV: interpretable phenotype-aware model for the prioritization of genes affected by structural variants</h1>

<div class="search-info"></div>

<p>Structural variants (SVs) are a significant source of genetic variation linked to phenotypic diversity and disease risk. Although long-read sequencing technologies can identify over 20,000 SVs in a human genome, understanding their functional implications remains a challenge. Current methods for detecting disease-related SVs focus primarily on deletions and duplications, and they are unable to pinpoint specific genes impacted by SVs, particularly for noncoding variants. In this study, we introduce PhenoSV, a machine-learning model that incorporates phenotype information to interpret all major types of SVs and the genes they affect. PhenoSV segments and annotates SVs with a range of genomic features, using a transformer-based architecture within a multiple-instance learning framework to predict their potential effects. By leveraging gene-phenotype associations, PhenoSV can prioritize SVs related to specific phenotypes. Extensive evaluation on diverse human SV datasets demonstrates PhenoSV’s superior performance compared to other methods. When applied to disease studies, PhenoSV effectively identifies disease-associated genes affected by SVs. PhenoSV is accessible through both a web server and a command-line tool, available at https://phenosv.wglab.org.</p>

<div class="citation-container">
  <div class="citation">
    
      <a href="https://www.ncbi.nlm.nih.gov/pubmed/38016949" class="citation-image" aria-label="PhenoSV: interpretable phenotype-aware model for the prioritization of genes affected by structural variants.">
        <img src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9a46/10684511/91e0cd125e1e/41467_2023_43651_Fig1_HTML.jpg" alt="PhenoSV: interpretable phenotype-aware model for the prioritization of genes affected by structural variants." loading="lazy" onerror="this.src = '/images/fallback.svg'; this.onerror = null;" />
      </a>
    

    <div class="citation-text">
      
      

      <a href="https://www.ncbi.nlm.nih.gov/pubmed/38016949" class="citation-title">
        PhenoSV: interpretable phenotype-aware model for the prioritization of genes affected by structural variants.
      </a>

      <div class="citation-authors" tabindex="0">
        Zhuoran Xu, Quan Li, Luigi Marchionni, Kai Wang

      </div>

      <div class="citation-details">
        <span class="citation-publisher">Nature communications</span>
        &nbsp;·&nbsp;
        <span class="citation-date">28 Nov 2023</span>
        &nbsp;·&nbsp;
        <span class="citation-id">pubmed:38016949</span>
      </div>

      
        

        

        
          


  <div class="tags">
    
      <a href="?search=&quot;tag: method&quot;" class="tag" data-tooltip="Show items with the tag &quot;method&quot;">
        method
      </a>
    
      <a href="?search=&quot;tag: cancer&quot;" class="tag" data-tooltip="Show items with the tag &quot;cancer&quot;">
        cancer
      </a>
    
  </div>


        
      
    </div>
  </div>
</div>]]></content><author><name>luigi-marchionni</name></author><category term="gene signature" /><category term="cancer" /><category term="structural variants" /><summary type="html"><![CDATA[PhenoSV: interpretable phenotype-aware model for the prioritization of genes affected by structural variants]]></summary><media:thumbnail xmlns:media="http://search.yahoo.com/mrss/" url="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9a46/10684511/91e0cd125e1e/41467_2023_43651_Fig1_HTML.jpg" /><media:content medium="image" url="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9a46/10684511/91e0cd125e1e/41467_2023_43651_Fig1_HTML.jpg" xmlns:media="http://search.yahoo.com/mrss/" /></entry><entry><title type="html">Using biological constraints to improve prediction in precision oncology</title><link href="https://marchionnilab.org/2023/03/17/post-1.html" rel="alternate" type="text/html" title="Using biological constraints to improve prediction in precision oncology" /><published>2023-03-17T00:00:00+00:00</published><updated>2025-02-24T20:09:32+00:00</updated><id>https://marchionnilab.org/2023/03/17/post-1</id><content type="html" xml:base="https://marchionnilab.org/2023/03/17/post-1.html"><![CDATA[<h1 id="using-biological-constraints-to-improve-prediction-in-precision-oncology">Using biological constraints to improve prediction in precision oncology</h1>

<div class="search-info"></div>

<p>Many gene signatures have been created using machine learning (ML) on omics data, but their clinical usefulness is often limited by poor interpretability and inconsistent performance. In this study, we highlight the importance of incorporating prior biological knowledge into the decision rules generated by ML methods to create more reliable classifiers. We tested this approach by applying various ML algorithms to gene expression data to predict three challenging cancer outcomes: bladder cancer progression to muscle-invasive disease, response to neoadjuvant chemotherapy in triple-negative breast cancer, and metastatic progression in prostate cancer. We developed two types of classifiers: mechanistic, which focused the training on features related to specific biological mechanisms, and agnostic, which did not include any prior biological knowledge. Mechanistic models showed equal or better performance compared to their agnostic counterparts, with the added benefit of improved interpretability. Our results emphasize the value of incorporating biological constraints to develop robust gene signatures with strong translational potential.</p>

<div class="citation-container">
  <div class="citation">
    
      <a href="https://www.ncbi.nlm.nih.gov/pubmed/36852282" class="citation-image" aria-label="Using biological constraints to improve prediction in precision oncology.">
        <img src="https://ars.els-cdn.com/content/image/1-s2.0-S2589004223001852-fx1.jpg" alt="Using biological constraints to improve prediction in precision oncology." loading="lazy" onerror="this.src = '/images/fallback.svg'; this.onerror = null;" />
      </a>
    

    <div class="citation-text">
      
      

      <a href="https://www.ncbi.nlm.nih.gov/pubmed/36852282" class="citation-title">
        Using biological constraints to improve prediction in precision oncology.
      </a>

      <div class="citation-authors" tabindex="0">
        Mohamed Omar, Wikum Dinalankara, Lotte Mulder, Tendai Coady, Claudio Zanettini, Eddie Luidy Imada, Laurent Younes, Donald Geman, Luigi Marchionni

      </div>

      <div class="citation-details">
        <span class="citation-publisher">iScience</span>
        &nbsp;·&nbsp;
        <span class="citation-date">02 Feb 2023</span>
        &nbsp;·&nbsp;
        <span class="citation-id">pubmed:36852282</span>
      </div>

      
        

        

        
          


  <div class="tags">
    
      <a href="?search=&quot;tag: cancer&quot;" class="tag" data-tooltip="Show items with the tag &quot;cancer&quot;">
        cancer
      </a>
    
      <a href="?search=&quot;tag: tumor-heterogeneity&quot;" class="tag" data-tooltip="Show items with the tag &quot;tumor-heterogeneity&quot;">
        tumor-heterogeneity
      </a>
    
      <a href="?search=&quot;tag: statistical-method&quot;" class="tag" data-tooltip="Show items with the tag &quot;statistical-method&quot;">
        statistical-method
      </a>
    
  </div>


        
      
    </div>
  </div>
</div>]]></content><author><name>luigi-marchionni</name></author><category term="gene signature" /><category term="cancer" /><category term="class prediction" /><category term="Notch signaling" /><category term="triple negative breast cancer" /><category term="neoadjuvant chemotherapy" /><summary type="html"><![CDATA[Using biological constraints to improve prediction in precision oncology]]></summary><media:thumbnail xmlns:media="http://search.yahoo.com/mrss/" url="https://www.cell.com/cms/10.1016/j.isci.2023.106108/asset/a5a2122a-2006-41b9-9430-b28bd10251fc/main.assets/fx1_lrg.jpg" /><media:content medium="image" url="https://www.cell.com/cms/10.1016/j.isci.2023.106108/asset/a5a2122a-2006-41b9-9430-b28bd10251fc/main.assets/fx1_lrg.jpg" xmlns:media="http://search.yahoo.com/mrss/" /></entry><entry><title type="html">REPAC: analysis of alternative polyadenylation from RNA-sequencing data</title><link href="https://marchionnilab.org/2023/02/10/post-1.html" rel="alternate" type="text/html" title="REPAC: analysis of alternative polyadenylation from RNA-sequencing data" /><published>2023-02-10T00:00:00+00:00</published><updated>2025-02-24T20:09:32+00:00</updated><id>https://marchionnilab.org/2023/02/10/post-1</id><content type="html" xml:base="https://marchionnilab.org/2023/02/10/post-1.html"><![CDATA[<h1 id="repac-analysis-of-alternative-polyadenylation-from-rna-sequencing-data">REPAC: analysis of alternative polyadenylation from RNA-sequencing data</h1>

<div class="search-info"></div>

<p>Alternative polyadenylation (APA) is a crucial post-transcriptional regulatory mechanism that plays a significant role in gene expression, cellular differentiation, and the development of various diseases, including cancer and neurological disorders. Although there are specialized sequencing techniques available to analyze polyadenylation sites, the availability of such data remains limited compared to the more commonly used RNA-sequencing data. This gap poses a challenge for large-scale studies of APA, particularly in clinical and research settings.</p>

<p>To overcome this limitation, we developed REPAC, an innovative framework that enables the analysis of APA directly from RNA-sequencing data. REPAC efficiently identifies and quantifies polyadenylation events without the need for specialized polyadenylation-specific sequencing methods. In this study, we apply REPAC to investigate the landscape of APA induced by the activation of B cells, providing insights into how APA contributes to cellular processes in immune response.</p>

<p>Additionally, we demonstrate that REPAC significantly outperforms other existing methods for APA analysis, showing a speed advantage of at least seven times faster, which makes it highly suitable for large-scale studies involving hundreds or even thousands of samples. The framework is designed to be computationally efficient and scalable, making it accessible for both small and large datasets. Furthermore, REPAC provides highly accurate results, offering an intuitive, user-friendly approach to APA analysis.</p>

<p>Overall, REPAC presents a powerful, accurate, and convenient solution for exploring the complexities of APA, enabling researchers to study its impact on gene regulation and disease with greater efficiency and precision.</p>

<div class="citation-container">
  <div class="citation">
    
      <a href="https://www.ncbi.nlm.nih.gov/pubmed/36759904" class="citation-image" aria-label="REPAC: analysis of alternative polyadenylation from RNA-sequencing data.">
        <img src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/381b/9912678/2411f65028a2/13059_2023_2865_Fig1_HTML.jpg" alt="REPAC: analysis of alternative polyadenylation from RNA-sequencing data." loading="lazy" onerror="this.src = '/images/fallback.svg'; this.onerror = null;" />
      </a>
    

    <div class="citation-text">
      
      

      <a href="https://www.ncbi.nlm.nih.gov/pubmed/36759904" class="citation-title">
        REPAC: analysis of alternative polyadenylation from RNA-sequencing data.
      </a>

      <div class="citation-authors" tabindex="0">
        Eddie L Imada, Christopher Wilks, Ben Langmead, Luigi Marchionni

      </div>

      <div class="citation-details">
        <span class="citation-publisher">Genome biology</span>
        &nbsp;·&nbsp;
        <span class="citation-date">09 Feb 2023</span>
        &nbsp;·&nbsp;
        <span class="citation-id">pubmed:36759904</span>
      </div>

      
        

        

        
          


  <div class="tags">
    
      <a href="?search=&quot;tag: post-trancriptional-regulation&quot;" class="tag" data-tooltip="Show items with the tag &quot;post-trancriptional-regulation&quot;">
        post-trancriptional-regulation
      </a>
    
      <a href="?search=&quot;tag: splicing&quot;" class="tag" data-tooltip="Show items with the tag &quot;splicing&quot;">
        splicing
      </a>
    
      <a href="?search=&quot;tag: cancer&quot;" class="tag" data-tooltip="Show items with the tag &quot;cancer&quot;">
        cancer
      </a>
    
      <a href="?search=&quot;tag: genomics&quot;" class="tag" data-tooltip="Show items with the tag &quot;genomics&quot;">
        genomics
      </a>
    
      <a href="?search=&quot;tag: transcriptomics&quot;" class="tag" data-tooltip="Show items with the tag &quot;transcriptomics&quot;">
        transcriptomics
      </a>
    
      <a href="?search=&quot;tag: method&quot;" class="tag" data-tooltip="Show items with the tag &quot;method&quot;">
        method
      </a>
    
  </div>


        
      
    </div>
  </div>
</div>]]></content><author><name>luigi-marchionni</name></author><category term="gene signature" /><category term="cancer" /><category term="class prediction" /><category term="Notch signaling" /><category term="triple negative breast cancer" /><category term="neoadjuvant chemotherapy" /><summary type="html"><![CDATA[REPAC: analysis of alternative polyadenylation from RNA-sequencing data]]></summary><media:thumbnail xmlns:media="http://search.yahoo.com/mrss/" url="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/381b/9912678/2411f65028a2/13059_2023_2865_Fig1_HTML.jpg" /><media:content medium="image" url="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/381b/9912678/2411f65028a2/13059_2023_2865_Fig1_HTML.jpg" xmlns:media="http://search.yahoo.com/mrss/" /></entry><entry><title type="html">Donor-derived acute myeloid leukemia in solid organ transplantation</title><link href="https://marchionnilab.org/2022/09/08/post-1.html" rel="alternate" type="text/html" title="Donor-derived acute myeloid leukemia in solid organ transplantation" /><published>2022-09-08T00:00:00+00:00</published><updated>2025-02-24T20:09:32+00:00</updated><id>https://marchionnilab.org/2022/09/08/post-1</id><content type="html" xml:base="https://marchionnilab.org/2022/09/08/post-1.html"><![CDATA[<h1 id="donor-derived-acute-myeloid-leukemia-in-solid-organ-transplantation">Donor-derived acute myeloid leukemia in solid organ transplantation</h1>

<div class="search-info"></div>

<p>We report the transmission of acute myeloid leukemia (AML) undetected at donation from a deceased organ donor to two kidneys and one liver recipients. We reviewed the medical records, and performed molecular analyses and whole exome sequencing (WES) to ascertain AML donor origin and its molecular evolution. The liver recipient was diagnosed 11 months after transplantation and died from complications 2 months later. The two kidney recipients (R1 and R2) were diagnosed 19 and 20 months after transplantation and both received treatment for leukemia. R1 died of complications 11 months after diagnosis, while R2 went into complete remission for 44 months, before relapsing. R2 died 10 months later of complications from allogenic bone marrow transplantation. Microsatellite analysis demonstrated donor chimerism in circulating cells from both kidney recipients. Targeted molecular analyses and medical records revealed NPM1 mutation present in the donor and recipients, while FLT3 was mutated only in R1. These findings were confirmed by WES, which revealed additional founder and clonal mutations, and HLA genomic loss in R2. In conclusion, we report the first in-depth genomic analysis of AML transmission following solid organ transplantation, revealing distinct clonal evolution, and providing a potential molecular explanation for tumor escape.</p>

<div class="citation-container">
  <div class="citation">
    
      <a href="https://www.ncbi.nlm.nih.gov/pubmed/37964363" class="citation-image" aria-label="Notch-based gene signature for predicting the response to neoadjuvant chemotherapy in triple-negative breast cancer.">
        <img src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0342/10647131/e40db7c7b497/12967_2023_4713_Fig1_HTML.jpg" alt="Notch-based gene signature for predicting the response to neoadjuvant chemotherapy in triple-negative breast cancer." loading="lazy" onerror="this.src = '/images/fallback.svg'; this.onerror = null;" />
      </a>
    

    <div class="citation-text">
      
      

      <a href="https://www.ncbi.nlm.nih.gov/pubmed/37964363" class="citation-title">
        Notch-based gene signature for predicting the response to neoadjuvant chemotherapy in triple-negative breast cancer.
      </a>

      <div class="citation-authors" tabindex="0">
        Mohamed Omar, Pier Vitale Nuzzo, Francesco Ravera, Sara Bleve, Giuseppe Nicolò Fanelli, Claudio Zanettini, Itzel Valencia, Luigi Marchionni

      </div>

      <div class="citation-details">
        <span class="citation-publisher">Journal of translational medicine</span>
        &nbsp;·&nbsp;
        <span class="citation-date">15 Nov 2023</span>
        &nbsp;·&nbsp;
        <span class="citation-id">pubmed:37964363</span>
      </div>

      
        

        

        
          


  <div class="tags">
    
      <a href="?search=&quot;tag: method&quot;" class="tag" data-tooltip="Show items with the tag &quot;method&quot;">
        method
      </a>
    
      <a href="?search=&quot;tag: structural-variants&quot;" class="tag" data-tooltip="Show items with the tag &quot;structural-variants&quot;">
        structural-variants
      </a>
    
  </div>


        
      
    </div>
  </div>
</div>]]></content><author><name>luigi-marchionni</name></author><category term="acute myeloid leukemia" /><category term="transplantation" /><category term="clonal hematopoiesis" /><category term="tumor evolution" /><summary type="html"><![CDATA[Donor-derived acute myeloid leukemia in solid organ transplantation]]></summary><media:thumbnail xmlns:media="http://search.yahoo.com/mrss/" url="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f438/9897593/c932219972b9/nihms-1837110-f0005.jpg" /><media:content medium="image" url="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f438/9897593/c932219972b9/nihms-1837110-f0005.jpg" xmlns:media="http://search.yahoo.com/mrss/" /></entry><entry><title type="html">Efficient representations of tumor diversity with paired DNA-RNA aberrations</title><link href="https://marchionnilab.org/2021/06/11/post-1.html" rel="alternate" type="text/html" title="Efficient representations of tumor diversity with paired DNA-RNA aberrations" /><published>2021-06-11T00:00:00+00:00</published><updated>2025-02-24T20:09:32+00:00</updated><id>https://marchionnilab.org/2021/06/11/post-1</id><content type="html" xml:base="https://marchionnilab.org/2021/06/11/post-1.html"><![CDATA[<h1 id="efficient-representations-of-tumor-diversity-with-paired-dna-rna-aberrations">Efficient representations of tumor diversity with paired DNA-RNA aberrations</h1>

<div class="search-info"></div>

<p>Cancer cells exhibit significant dysregulation in key regulatory pathways due to well-documented mutations and other DNA-related abnormalities. These disruptions, however, are not uniform; they display considerable heterogeneity in their identity, frequency, and location across individuals with the same cancer type or subtype. This variation naturally extends to the transcriptome, resulting in a wide range of dysregulated gene expression patterns. It has been argued that understanding the heterogeneity of both DNA and RNA molecular profiles in a more integrative and quantitative manner is essential for advancing systematic approaches to alternative therapies and improving the accuracy of cancer prognosis and treatment prediction.</p>

<p>In this work, we present a novel representation of multi-omics profiles that is rich enough to account for the observed heterogeneity in cancer and facilitates the development of quantitative, integrated metrics of variation. Building on the network of molecular interactions provided by Reactome, we construct a library of “paired DNA-RNA aberrations.” These paired aberrations capture prototypical and recurrent patterns of dysregulation in cancer. Each pair, called a “Source-Target Pair” (STP), consists of a “source” regulatory gene and a “target” gene whose expression is likely controlled by the source gene. An STP is deemed “aberrant” if the source gene undergoes a DNA-level aberration (such as mutation, deletion, or duplication) and the target gene exhibits an RNA-level aberration, meaning its expression deviates from the normal range.</p>

<p>Given a set of M STPs, a sample profile can be classified into one of the 2^M possible configurations. We focus on subsets of STPs and corresponding reduced configurations, selecting tissue-specific minimal coverings. A minimal covering is the smallest group of STPs such that every sample in the population exhibits at least one aberrant STP from that group. These minimal coverings are computed using integer programming. Once a covering is defined, we can quantify cross-sample diversity by examining the variability of aberrant STPs across samples, which is measured using the entropy of the distribution over configurations.</p>

<p>We apply this methodology to data from the TCGA (The Cancer Genome Atlas) for six distinct tumor types: breast, prostate, lung, colon, liver, and kidney cancers. This approach allows us to efficiently simplify the complex molecular landscape observed across different cancer populations, uncovering novel signatures of molecular alterations that would not be detectable through traditional frequency-based methods. Our analysis reveals a stable pattern of cancer heterogeneity across tumor phenotypes: entropy increases as disease severity worsens.</p>

<p>This framework offers a powerful approach to understanding the intricate molecular landscape of cancer. It is well-suited to accommodate the growing complexity of cancer genomes and epigenomes as large consortia projects continue to expand, providing a valuable tool for refining cancer classification and improving therapeutic strategies based on molecular profiles.</p>

<div class="citation-container">
  <div class="citation">
    
      <a href="https://www.ncbi.nlm.nih.gov/pubmed/34115745" class="citation-image" aria-label="Efficient representations of tumor diversity with paired DNA-RNA aberrations.">
        <img src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1b82/8221796/8fb0565b0a4d/pcbi.1008944.g001.jpg" alt="Efficient representations of tumor diversity with paired DNA-RNA aberrations." loading="lazy" onerror="this.src = '/images/fallback.svg'; this.onerror = null;" />
      </a>
    

    <div class="citation-text">
      
      

      <a href="https://www.ncbi.nlm.nih.gov/pubmed/34115745" class="citation-title">
        Efficient representations of tumor diversity with paired DNA-RNA aberrations.
      </a>

      <div class="citation-authors" tabindex="0">
        Qian Ke, Wikum Dinalankara, Laurent Younes, Donald Geman, Luigi Marchionni

      </div>

      <div class="citation-details">
        <span class="citation-publisher">PLoS computational biology</span>
        &nbsp;·&nbsp;
        <span class="citation-date">11 Jun 2021</span>
        &nbsp;·&nbsp;
        <span class="citation-id">pubmed:34115745</span>
      </div>

      
        

        

        
          


  <div class="tags">
    
      <a href="?search=&quot;tag: cancer&quot;" class="tag" data-tooltip="Show items with the tag &quot;cancer&quot;">
        cancer
      </a>
    
      <a href="?search=&quot;tag: tumor-heterogeneity&quot;" class="tag" data-tooltip="Show items with the tag &quot;tumor-heterogeneity&quot;">
        tumor-heterogeneity
      </a>
    
      <a href="?search=&quot;tag: statistical-method&quot;" class="tag" data-tooltip="Show items with the tag &quot;statistical-method&quot;">
        statistical-method
      </a>
    
      <a href="?search=&quot;tag: resource&quot;" class="tag" data-tooltip="Show items with the tag &quot;resource&quot;">
        resource
      </a>
    
  </div>


        
      
    </div>
  </div>
</div>]]></content><author><name>luigi-marchionni</name></author><category term="tumor heterogenity" /><category term="cancer" /><category term="tumor modeling" /><summary type="html"><![CDATA[Efficient representations of tumor diversity with paired DNA-RNA aberrations]]></summary><media:thumbnail xmlns:media="http://search.yahoo.com/mrss/" url="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1b82/8221796/8fb0565b0a4d/pcbi.1008944.g001.jpg" /><media:content medium="image" url="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1b82/8221796/8fb0565b0a4d/pcbi.1008944.g001.jpg" xmlns:media="http://search.yahoo.com/mrss/" /></entry><entry><title type="html">An R package for divergence analysis of omics data</title><link href="https://marchionnilab.org/2021/04/05/post-1.html" rel="alternate" type="text/html" title="An R package for divergence analysis of omics data" /><published>2021-04-05T00:00:00+00:00</published><updated>2025-02-24T20:09:32+00:00</updated><id>https://marchionnilab.org/2021/04/05/post-1</id><content type="html" xml:base="https://marchionnilab.org/2021/04/05/post-1.html"><![CDATA[<h1 id="an-r-package-for-divergence-analysis-of-omics-data">An R package for divergence analysis of omics data</h1>

<div class="search-info"></div>

<p>Given the ever-increasing amount of high-dimensional and complex omics data becoming available, it is increasingly important to discover simple but effective methods of analysis. Divergence analysis transforms each entry of a high-dimensional omics profile into a digitized (binary or ternary) code based on the deviation of the entry from a given baseline population. This is a novel framework that is significantly different from existing omics data analysis methods: it allows digitization of continuous omics data at the univariate or multivariate level, facilitates sample level analysis, and is applicable on many different omics platforms. The divergence package, available on the R platform through the Bioconductor repository collection, provides easy-to-use functions for carrying out this transformation. Here we demonstrate how to use the package with data from the Cancer Genome Atlas.</p>

<div class="citation-container">
  <div class="citation">
    
      <a href="https://www.ncbi.nlm.nih.gov/pubmed/33819273" class="citation-image" aria-label="An R package for divergence analysis of omics data.">
        <img src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1cc9/8021195/4749a0e92fd5/pone.0249002.g003.jpg" alt="An R package for divergence analysis of omics data." loading="lazy" onerror="this.src = '/images/fallback.svg'; this.onerror = null;" />
      </a>
    

    <div class="citation-text">
      
      

      <a href="https://www.ncbi.nlm.nih.gov/pubmed/33819273" class="citation-title">
        An R package for divergence analysis of omics data.
      </a>

      <div class="citation-authors" tabindex="0">
        Wikum Dinalankara, Qian Ke, Donald Geman, Luigi Marchionni

      </div>

      <div class="citation-details">
        <span class="citation-publisher">PloS one</span>
        &nbsp;·&nbsp;
        <span class="citation-date">05 Apr 2021</span>
        &nbsp;·&nbsp;
        <span class="citation-id">pubmed:33819273</span>
      </div>

      
        

        

        
          


  <div class="tags">
    
      <a href="?search=&quot;tag: method&quot;" class="tag" data-tooltip="Show items with the tag &quot;method&quot;">
        method
      </a>
    
      <a href="?search=&quot;tag: genomics&quot;" class="tag" data-tooltip="Show items with the tag &quot;genomics&quot;">
        genomics
      </a>
    
      <a href="?search=&quot;tag: transcriptomics&quot;" class="tag" data-tooltip="Show items with the tag &quot;transcriptomics&quot;">
        transcriptomics
      </a>
    
      <a href="?search=&quot;tag: heterogeneity&quot;" class="tag" data-tooltip="Show items with the tag &quot;heterogeneity&quot;">
        heterogeneity
      </a>
    
  </div>


        
      
    </div>
  </div>
</div>]]></content><author><name>luigi-marchionni</name></author><category term="bioconductor" /><category term="bioinformatics" /><category term="data analysis" /><category term="omics" /><summary type="html"><![CDATA[An R package for divergence analysis of omics data]]></summary><media:thumbnail xmlns:media="http://search.yahoo.com/mrss/" url="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1cc9/8021195/4749a0e92fd5/pone.0249002.g003.jpg" /><media:content medium="image" url="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1cc9/8021195/4749a0e92fd5/pone.0249002.g003.jpg" xmlns:media="http://search.yahoo.com/mrss/" /></entry><entry><title type="html">Our paper on HDAC Inhibition</title><link href="https://marchionnilab.org/2013/07/19/post-1.html" rel="alternate" type="text/html" title="Our paper on HDAC Inhibition" /><published>2013-07-19T00:00:00+00:00</published><updated>2025-02-24T20:09:32+00:00</updated><id>https://marchionnilab.org/2013/07/19/post-1</id><content type="html" xml:base="https://marchionnilab.org/2013/07/19/post-1.html"><![CDATA[<h1 id="genomic-responses-to-hdac-inhibitors-in-prostate-cancer-cells">Genomic responses to HDAC inhibitors in prostate cancer cells</h1>

<div class="search-info"></div>

<p>Histone deacetylases (HDACs) have become significant targets for cancer therapy. HDAC inhibitors (HDACis) are well tolerated by patients and have been approved for treating cutaneous T-cell lymphoma (CTCL). To enhance the clinical benefits of HDACis in solid tumors, combination therapies involving HDACis may be considered. In this study, we used Analysis of Functional Annotation (AFA) to create a comprehensive list of genes and pathways affected by HDACi treatment in prostate cancer cells. This method provides an unbiased and objective way to analyze high-throughput data. By performing AFA on gene expression data from prostate cancer cell lines DU-145 (HDACi-sensitive) and PC3 (HDACi-resistant), treated with HDACis valproic acid or vorinostat, we identified biological processes altered by HDACis, suggesting potential targets for combination therapies. Our analysis revealed that HDAC inhibition led to, among other effects, upregulation of major histocompatibility complex (MHC) genes and disruption of the mitotic spindle checkpoint due to downregulation of mitosis-related genes. These findings were further validated through AFA on publicly available datasets of HDACi-treated prostate cancer cells. In total, we analyzed 375 microarrays from HDACi-treated and control prostate cancer cells. All results from this extensive analysis are made available as an online resource (accessible at the journal’s website and at http://marchionni.org/HDACIs.html). By publishing this data, we aim to improve the understanding of cellular changes following HDAC inhibition and identify new potential combination strategies for treating prostate cancer.</p>

<p>Here is <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3883768/">our work</a> 
on transcriptional responses to HDAC inhibitors in prostate cancer.
Extensive supplementary material is also available <a href="HDACIs.html">here</a></p>

<p>Also, please visit <a href="https://www.urotoday.com/recent-abstracts/urologic-oncology/mcrpc-treatment/70874-analysis-of-the-genomic-response-of-human-prostate-cancer-cells-to-histone-deacetylase-inhibitors-beyond-the-abstract-by-michel-d-wissing-madeleine-s-q-kortenhorst-and-luigi-marchionni.html">this page</a> for commentary on our manuscript</p>

<div class="citation-container">
  <div class="citation">
    
      <a href="https://www.ncbi.nlm.nih.gov/pubmed/23880963" class="citation-image" aria-label="Analysis of the genomic response of human prostate cancer cells to histone deacetylase inhibitors.">
        <img src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1d82/3883768/24594ab2add1/epi-8-907-g1.jpg" alt="Analysis of the genomic response of human prostate cancer cells to histone deacetylase inhibitors." loading="lazy" onerror="this.src = '/images/fallback.svg'; this.onerror = null;" />
      </a>
    

    <div class="citation-text">
      
      

      <a href="https://www.ncbi.nlm.nih.gov/pubmed/23880963" class="citation-title">
        Analysis of the genomic response of human prostate cancer cells to histone deacetylase inhibitors.
      </a>

      <div class="citation-authors" data-tooltip="Madeleine S Q Kortenhorst, Michel D Wissing, Ronald Rodríguez, Sushant K Kachhap, Judith J M Jans, Petra Van der Groep, Henk M W Verheul, Anuj Gupta, Paul O Aiyetan, Elsken van der Wall, Michael A Carducci, Paul J Van Diest, Luigi Marchionni" tabindex="0">
        Madeleine S Q Kortenhorst, Michel D Wissing, Ronald Rodríguez, Sushant K Kachhap, Judith J M Jans, …, Paul O Aiyetan, Elsken van der Wall, Michael A Carducci, Paul J Van Diest, Luigi Marchionni

      </div>

      <div class="citation-details">
        <span class="citation-publisher">Epigenetics</span>
        &nbsp;·&nbsp;
        <span class="citation-date">19 Jul 2013</span>
        &nbsp;·&nbsp;
        <span class="citation-id">pubmed:23880963</span>
      </div>

      
        

        

        
          


  <div class="tags">
    
      <a href="?search=&quot;tag: prostate-cancer&quot;" class="tag" data-tooltip="Show items with the tag &quot;prostate-cancer&quot;">
        prostate-cancer
      </a>
    
      <a href="?search=&quot;tag: epigenetics&quot;" class="tag" data-tooltip="Show items with the tag &quot;epigenetics&quot;">
        epigenetics
      </a>
    
      <a href="?search=&quot;tag: combination-therapy&quot;" class="tag" data-tooltip="Show items with the tag &quot;combination-therapy&quot;">
        combination-therapy
      </a>
    
      <a href="?search=&quot;tag: gene-expression&quot;" class="tag" data-tooltip="Show items with the tag &quot;gene-expression&quot;">
        gene-expression
      </a>
    
  </div>


        
      
    </div>
  </div>
</div>]]></content><author><name>luigi-marchionni</name></author><category term="medicine" /><category term="cancer" /><category term="class prediction" /><category term="breast cancer" /><category term="epigenomics" /><summary type="html"><![CDATA[Genomic responses to HDAC inhibitors in prostate cancer cells]]></summary><media:thumbnail xmlns:media="http://search.yahoo.com/mrss/" url="https://marchionnilab.org/images/science/HDACIs.png" /><media:content medium="image" url="https://marchionnilab.org/images/science/HDACIs.png" xmlns:media="http://search.yahoo.com/mrss/" /></entry><entry><title type="html">Predicting breast cancer metastatic progression</title><link href="https://marchionnilab.org/2013/05/13/post-1.html" rel="alternate" type="text/html" title="Predicting breast cancer metastatic progression" /><published>2013-05-13T00:00:00+00:00</published><updated>2025-02-24T20:09:32+00:00</updated><id>https://marchionnilab.org/2013/05/13/post-1</id><content type="html" xml:base="https://marchionnilab.org/2013/05/13/post-1.html"><![CDATA[<h1 id="a-simple-and-reproducible-breast-cancer-prognostic-test">A simple and reproducible breast cancer prognostic test</h1>

<div class="search-info"></div>

<p>In this study we analyzed the expression of the genes constituting the 70-gene breast cancer prognostic signature, as implemented in the MammaPrint assay, to develop novel and simple prognostic predictors based on the Top-Scoring-Pair (TSP) algorithm. 
Visit this <a href="https://bmcgenomics.biomedcentral.com/articles/10.1186/1471-2164-14-336">page</a>
to read the original manuscript.</p>

<p><em>Background.</em> A limited number of gene expression-based prognostic and predictive tests are currently available as reference laboratory tests. While some of these have been successful, many other genomic-based predictors have been found to contain flaws and errors, resulting in a low success rate for developing clinically useful genomic signatures. These issues have raised concerns regarding the protocols used in computational research. Consequently, there is an increasing demand for a standardized approach to the reproducible development of genomic signatures that emphasizes full transparency, data sharing, and statistical rigor.</p>

<p><em>Results.</em> In this study, we present the first fully reproducible analysis of the data used to train and test MammaPrint, an FDA-cleared prognostic test for breast cancer based on a 70-gene expression signature. We provide all the necessary software and documentation to enable researchers to build and assess genomic classifiers using these data. As a demonstration of the value of this reproducible research resource, we develop a simple prognostic classifier utilizing just 16 genes from the MammaPrint signature, achieving the same level of accuracy in predicting 5-year disease-free survival.</p>

<p><em>Conclusions.</em> Our study offers a model for the reproducible development of computational algorithms aimed at identifying prognostic biomarkers in the era of personalized medicine.</p>

<div class="citation-container">
  <div class="citation">
    
      <a href="https://www.ncbi.nlm.nih.gov/pubmed/23682826" class="citation-image" aria-label="A simple and reproducible breast cancer prognostic test.">
        <img src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0046/3662649/53f774f82d61/1471-2164-14-336-3.jpg" alt="A simple and reproducible breast cancer prognostic test." loading="lazy" onerror="this.src = '/images/fallback.svg'; this.onerror = null;" />
      </a>
    

    <div class="citation-text">
      
      

      <a href="https://www.ncbi.nlm.nih.gov/pubmed/23682826" class="citation-title">
        A simple and reproducible breast cancer prognostic test.
      </a>

      <div class="citation-authors" tabindex="0">
        Luigi Marchionni, Bahman Afsari, Donald Geman, Jeffrey T Leek

      </div>

      <div class="citation-details">
        <span class="citation-publisher">BMC genomics</span>
        &nbsp;·&nbsp;
        <span class="citation-date">17 May 2013</span>
        &nbsp;·&nbsp;
        <span class="citation-id">pubmed:23682826</span>
      </div>

      
        

        

        
          


  <div class="tags">
    
      <a href="?search=&quot;tag: breast-cancer&quot;" class="tag" data-tooltip="Show items with the tag &quot;breast-cancer&quot;">
        breast-cancer
      </a>
    
      <a href="?search=&quot;tag: classification&quot;" class="tag" data-tooltip="Show items with the tag &quot;classification&quot;">
        classification
      </a>
    
      <a href="?search=&quot;tag: single-cell&quot;" class="tag" data-tooltip="Show items with the tag &quot;single-cell&quot;">
        single-cell
      </a>
    
      <a href="?search=&quot;tag: gene-expression-signature&quot;" class="tag" data-tooltip="Show items with the tag &quot;gene-expression-signature&quot;">
        gene-expression-signature
      </a>
    
      <a href="?search=&quot;tag: statistical-method&quot;" class="tag" data-tooltip="Show items with the tag &quot;statistical-method&quot;">
        statistical-method
      </a>
    
  </div>


        
      
    </div>
  </div>
</div>]]></content><author><name>luigi-marchionni</name></author><category term="biology" /><category term="medicine" /><category term="breast cancer" /><category term="prognosis" /><category term="gene expression" /><summary type="html"><![CDATA[A simple and reproducible breast cancer prognostic test]]></summary><media:thumbnail xmlns:media="http://search.yahoo.com/mrss/" url="https://marchionnilab.org/images/science/kTSPbreast.jpg" /><media:content medium="image" url="https://marchionnilab.org/images/science/kTSPbreast.jpg" xmlns:media="http://search.yahoo.com/mrss/" /></entry></feed>